{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:45:06Z","timestamp":1792637106856,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) is becoming standard of care for men with biochemical recurrence (BCR) of prostate cancer. The implications of a negative PSMA PET\/CT scan in this population remain unclear. This study aims to assess the outcome of patients with BCR post radical prostatectomy (RP) who have negative [<jats:sup>18<\/jats:sup>F]DCFPyL PET\/CT scan at relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a post-hoc subgroup analysis of a prospective non randomized clinical trial. One hundred and one patients (median age, 75 years) with BCR after RP, who tested negative on [<jats:sup>18<\/jats:sup>F]DCFPyL PET\/CT and subsequently either underwent salvage radiotherapy (sRT) with or without androgen deprivation therapy (ADT) or were followed without active treatment, were included. Freedom from progression (FFP) after negative PSMA PET\/CT was determined based on follow-up imaging selected as per clinical practice. Uni- and multivariate Cox regression analyses were performed to examine the association of patients' characteristics, tumor-specific variables, and treatment with clinical progression at the last follow-up. FFP at 1-, 2-, and 3-year were reported using Kaplan Meier analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median PSA level at PET\/CT was 0.56 ng\/mL (range, 0.4\u201311.3). Sixty five (64%) patients were followed without receiving further treatment, and 36 (36%) received sRT (18% to the prostate bed only and 18% to the prostate bed and pelvic lymph nodes) within 3 months of the PSMA PET. Seventeen of the sRT patients (17 of 36, 47%) received concomitant androgen deprivation therapy (ADT). Median follow-up was 39 months. Subsequent clinical progression was detected in 21 patients (21%), with 52% in pelvic lymph nodes, 52% in the prostatic fossa, 19% in distant lymph nodes, 14% in lungs, and 10% in bones. The FFP was 95% (95% CI: 91%-99%) at 12 months, 87% (95% CI: 81%-94%) at 24 months, and 79% (95% CI: 71%-88%) at 36 months. Multivariate Cox regression analysis revealed that an initial International Society of Urological Pathology (ISUP) grade 5 was significantly associated with clinical progression at the last follow-up (hazard ratio, 5.1, <jats:italic>P<\/jats:italic> value, 0.04). Furthermore, the receipt of sRT correlated significantly with lower clinical progression at the last follow-up (hazard ratio, 0.2, <jats:italic>P<\/jats:italic> value, 0.03), whereas other clinical and tumor-specific parameters did not. Following surveillance-only and sRT, 29% (19 of 65) and 6% (2 of 36) of patients, respectively, showed clinical progression. In the sRT group, no significant difference was observed in FFP between patients who underwent sRT to the prostatic fossa versus those who received sRT to the prostatic fossa and pelvic lymph nodes, although the numbers in these groups were small.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study suggests that salvage radiotherapy is associated with a decreased or delayed clinical progression in patients with biochemical recurrence following radical prostatectomy who have negative PSMA PET\/CT scan results. The analysis also underscores the prognostic significance of the initial ISUP grade, with ISUP grade 5 being associated with worse outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Registered September 14, 2016; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02899312\">NCT02899312<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-024-00752-1","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:02:08Z","timestamp":1724979728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prognostic significance of a negative PSMA PET\/CT in biochemical recurrence of prostate cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Sara","family":"Harsini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Plaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Saprunoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tyldesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7995-3581","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"3","key":"752_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"752_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cncr.10657","volume":"95","author":"AV D'Amico","year":"2002","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95(2):281\u20136.","journal-title":"Cancer"},{"issue":"3","key":"752_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/01.ju.0000152556.53602.64","volume":"173","author":"EM Horwitz","year":"2005","unstructured":"Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005;173(3):797\u2013802.","journal-title":"J Urol"},{"issue":"24","key":"752_CR4","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","volume":"24","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24(24):3973\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"752_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RC, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263\u201382.","journal-title":"Eur Urol."},{"issue":"2","key":"752_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.eururo.2011.03.011","volume":"60","author":"DC Chade","year":"2011","unstructured":"Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60(2):205\u201310.","journal-title":"Eur Urol"},{"issue":"11","key":"752_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.diii.2019.07.001","volume":"100","author":"M Barat","year":"2019","unstructured":"Barat M, Colleter L, Mongiat-Artus P, Jolibois Z, Quero L, Hennequin C, et al. Salvage cryoablation for local recurrence of prostatic cancer after curative therapy. Diagn Interv Imaging. 2019;100(11):679\u201387.","journal-title":"Diagn Interv Imaging"},{"issue":"5","key":"752_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2967\/jnumed.117.204032","volume":"59","author":"EE Parent","year":"2018","unstructured":"Parent EE, Schuster DM. Update on 18F-fluciclovine PET for prostate cancer imaging. J Nucl Med. 2018;59(5):733\u20139.","journal-title":"J Nucl Med"},{"issue":"2","key":"752_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2967\/jnumed.120.260455","volume":"62","author":"G Carlucci","year":"2021","unstructured":"Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S. 68Ga-PSMA-11 NDA approval: a novel and successful academic partnership. J Nucl Med. 2021;62(2):149\u201355.","journal-title":"J Nucl Med"},{"issue":"6","key":"752_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.121.262989","volume":"63","author":"H Song","year":"2022","unstructured":"Song H, Iagaru A, Rowe SP. 18F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval. J Nucl Med. 2022;63(6):855\u20139.","journal-title":"J Nucl Med"},{"issue":"10","key":"752_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21(10):1331\u201340.","journal-title":"Lancet Oncol."},{"issue":"10260","key":"752_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413\u201321.","journal-title":"Lancet"},{"issue":"10","key":"752_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341\u201352.","journal-title":"Lancet Oncol"},{"issue":"10260","key":"752_CR14","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422\u201331.","journal-title":"Lancet"},{"issue":"44","key":"752_CR15","first-page":"55","volume":"9","author":"K Bouchelouche","year":"2010","unstructured":"Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen\u2014a target for imaging and therapy with radionuclides. Discov Med. 2010;9(44):55.","journal-title":"Discov Med."},{"issue":"24","key":"752_CR16","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.3390\/cancers14246194","volume":"14","author":"A Sabbagh","year":"2022","unstructured":"Sabbagh A, Mohamad O, Lichter KE, Hope TAJC. Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. Cancers (Basel). 2022;14(24):6194.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"752_CR17","first-page":"127","volume":"9","author":"G Treglia","year":"2019","unstructured":"Treglia G, Mestre RP, Ferrari M, Bosetti DG, Pascale M, Oikonomou E, et al. Radiolabelled choline versus PSMA PET\/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imaging. 2019;9(2):127.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"752_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ijrobp.2022.04.048","volume":"113","author":"C Zamboglou","year":"2022","unstructured":"Zamboglou C, Strouthos I, Sahlmann J, Farolfi A, Serani F, Medici F, et al. Metastasis-free survival and patterns of distant metastatic disease after prostate-specific membrane antigen positron emission tomography (PSMA-PET)-guided salvage radiation therapy in recurrent or persistent prostate cancer after prostatectomy. Int J Radiat Oncol Biol Phys. 2022;113(5):1015\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"752_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3390\/cancers15010247","volume":"15","author":"L Bianchi","year":"2022","unstructured":"Bianchi L, Ceci F, Costa F, Balestrazzi E, Droghetti M, Piazza P, et al. The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence. Cancers (Basel). 2022;15(1):247.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"752_CR20","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3390\/diagnostics12112594","volume":"12","author":"AD Combes","year":"2022","unstructured":"Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, et al. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics (Basel). 2022;12(11):2594.","journal-title":"Diagnostics (Basel)"},{"key":"752_CR21","doi-asserted-by":"publisher","first-page":"109556","DOI":"10.1016\/j.ejrad.2021.109556","volume":"136","author":"J Morawitz","year":"2021","unstructured":"Morawitz J, Kirchner J, Lakes J, Bruckmann N, Mamlins E, Hiester A, et al. PSMA PET\/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: comparison of detection rates and therapeutic implications. Eur J Radiol. 2021;136.","journal-title":"Eur J Radiol."},{"issue":"2","key":"752_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jama.2019.20675","volume":"323","author":"KE Hoffman","year":"2020","unstructured":"Hoffman KE, Penson DF, Zhao Z, Huang L-C, Conwill R, Laviana AA, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323(2):149\u201363.","journal-title":"JAMA"},{"issue":"2","key":"752_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00259-023-06438-3","volume":"51","author":"S Adebahr","year":"2024","unstructured":"Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, et al. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51(2):558\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"752_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00259-020-04914-8","volume":"48","author":"M Celli","year":"2021","unstructured":"Celli M, De Giorgi U, Caroli P, Di Iorio V, Fantini L, Rossetti V, et al. Clinical value of negative (68)Ga-PSMA PET\/CT in the management of biochemical recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(1):87\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"752_CR25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.2967\/jnumed.119.235028","volume":"61","author":"L Emmett","year":"2020","unstructured":"Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, et al. 3-Year Freedom from Progression After (68)Ga-PSMA PET\/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. J Nucl Med. 2020;61(6):866\u201372.","journal-title":"J Nucl Med"},{"key":"752_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109678","volume":"184","author":"S Scharl","year":"2023","unstructured":"Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, et al. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. Radiother Oncol. 2023;184: 109678.","journal-title":"Radiother Oncol"},{"issue":"9","key":"752_CR27","first-page":"2212","volume":"12","author":"S Harsini","year":"2022","unstructured":"Harsini S, Wilson D, B\u00e9nard F. PSA-Stratified Performance of [(18)F]DCFPyL PET\/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy. Diagnostics (Basel, Switzerland). 2022;12(9):2212.","journal-title":"Diagnostics (Basel, Switzerland)."},{"key":"752_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-016-0195-6","volume":"6","author":"V Bouvet","year":"2016","unstructured":"Bouvet V, Wuest M, Jans H-S, Janzen N, Genady AR, Valliant JF, et al. Automated synthesis of [18 F] DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. EJNMMI Res. 2016;6:1\u201315.","journal-title":"EJNMMI Res"},{"issue":"4","key":"752_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Euro Urol. 2020;77(4):403\u201317.","journal-title":"Euro Urol"},{"key":"752_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.urology.2018.12.055","volume":"129","author":"L Boreta","year":"2019","unstructured":"Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, et al. Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy. Urology. 2019;129:165\u201371.","journal-title":"Urology"},{"issue":"8","key":"752_CR31","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/pros.23347","volume":"77","author":"G Habl","year":"2017","unstructured":"Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, et al. 68Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment. Prostate. 2017;77(8):920\u20137.","journal-title":"Prostate"},{"issue":"1","key":"752_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40644-023-00543-0","volume":"23","author":"S Harsini","year":"2023","unstructured":"Harsini S, Wilson D, Saprunoff H, Allan H, Gleave M, Goldenberg L, et al. Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET\/CT-directed radiotherapy or surgery without systemic therapy. Cancer Imaging. 2023;23(1):27.","journal-title":"Cancer Imaging"},{"issue":"1","key":"752_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-671","volume":"14","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14(1):1\u20136.","journal-title":"BMC Cancer"},{"key":"752_CR34","first-page":"1","volume":"42","author":"NI Simon","year":"2022","unstructured":"Simon NI, Parker C, Hope TA. Paller CJJASoCOEB. Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. 2022;42:1\u20138.","journal-title":"Best Approaches and Updates for Prostate Cancer Biochemical Recurrence"},{"issue":"2","key":"752_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2967\/jnumed.117.201749","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59(2):230\u20137.","journal-title":"J Nucl Med."},{"issue":"4","key":"752_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.121.262412","volume":"63","author":"M Abghari-Gerst","year":"2022","unstructured":"Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, et al. A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. J Nucl Med. 2022;63(4):567\u201372","journal-title":"J Nucl Med"},{"issue":"1","key":"752_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12885-022-09283-z","volume":"22","author":"C M\u00e9nard","year":"2022","unstructured":"M\u00e9nard C, Young S, Zukotynski K, Hamilton RJ, B\u00e9nard F, Yip S, et al. PSMA PET\/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. BMC Cancer. 2022;22(1):251.","journal-title":"BMC Cancer"},{"issue":"8","key":"752_CR38","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1200\/JCO.2014.59.0026","volume":"33","author":"RB Den","year":"2015","unstructured":"Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33(8):944.","journal-title":"J Clin Oncol"},{"issue":"3","key":"752_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/pcan.2016.15","volume":"19","author":"A Ross","year":"2016","unstructured":"Ross A, Den R, Yousefi K, Trock B, Tosoian J, Davicioni E, et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis. 2016;19(3):277\u201382.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"13","key":"752_CR40","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.22.02489","volume":"41","author":"D Tilki","year":"2023","unstructured":"Tilki D, Chen M-H, Wu J, Huland H, Graefen M, Mohamad O, et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. 2023;41(13):2428.","journal-title":"J Clin Oncol"},{"issue":"11","key":"752_CR41","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S1470-2045(16)30491-0","volume":"17","author":"SG Zhao","year":"2016","unstructured":"Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HAD, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016;17(11):1612\u201320.","journal-title":"Lancet Oncol."},{"issue":"9","key":"752_CR42","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","volume":"33","author":"A Dal Pra","year":"2022","unstructured":"Dal Pra A, Ghadjar P, Hayoz S, Liu V, Spratt D, Thompson D, et al. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy\u2013an ancillary study of the SAKK 09\/10 randomized clinical trial. Ann Oncol. 2022;33(9):950\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"752_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52\u201361.","journal-title":"J Urol"},{"key":"752_CR44","doi-asserted-by":"publisher","first-page":"1544208","DOI":"10.1155\/2021\/1544208","volume":"2021","author":"S McGeorge","year":"2021","unstructured":"McGeorge S, Kwok M, Jiang A, Emmett L, Pattison DA, Thomas PA, et al. Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review. Adv Urol. 2021;2021:1544208.","journal-title":"Adv Urol."},{"issue":"102","key":"752_CR45","doi-asserted-by":"publisher","first-page":"37676","DOI":"10.18632\/oncotarget.26481","volume":"9","author":"SA Harmon","year":"2018","unstructured":"Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, et al. A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET\/CT: Discordant uptake in the same lesion. Oncotarget. 2018;9(102):37676.","journal-title":"Oncotarget"},{"issue":"10338","key":"752_CR46","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399(10338):1886\u2013901.","journal-title":"Lancet"},{"issue":"1","key":"752_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13550-022-00913-y","volume":"12","author":"ML Donswijk","year":"2022","unstructured":"Donswijk ML, Wondergem M, de Wit-van der Veen L, Bruin NM, van Leeuwen PJ, van der Poel HG, et al. Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET\/CT: a single-centre retrospective study. EJNMMI Res. 2022;12(1):42.","journal-title":"EJNMMI Res."},{"key":"752_CR48","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00259-018-3989-0","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, B\u00f6gemann M, Wagner S, Sch\u00e4fers M, Stegger L, et al. 18 F-PSMA-1007 PET\/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45:1329\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"752_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/RLU.0000000000004108","volume":"47","author":"F Rosar","year":"2022","unstructured":"Rosar F, Bartholom\u00e4 M, Maus S, Priv\u00e9 BM, Khreish F, Franssen GM, et al. 89Zr-PSMA-617 PET\/CT may reveal local recurrence of prostate cancer unidentified by 68Ga-PSMA-11 PET\/CT. Clin Nucl Med. 2022;47(5):435\u20136.","journal-title":"Clin Nucl Med"},{"issue":"10","key":"752_CR50","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00259-017-3743-z","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, et al. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging. 2017;44(10):1647\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-024-00752-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:05:34Z","timestamp":1725023134000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-024-00752-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1186\/s40644-024-00752-1","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the UBC\/BC Cancer Research Ethics Board and by Health Canada (ethics code H16-01551).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}